focus -WSS

focus

author：knowledge 2025-10-01 21:09:37 - browse：24

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Dozens dead from Maui wildfires: What we know about the victims

WSS

Biogen’s boardroom scandal saddles CEO with first crisis

Stories you might have missed in 2023: health, science, medicine

Novo Nordisk touts Wegovy study, but still struggling with supply

Surge in Apellis stock fueled by confidence in safety of its eye drug

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Nonprofit, backed by Microsoft, to certify AI tools in health care

knowledge

focus

explore

23andMe had bad news about my health. I wish a person had delivered it

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

The cancer drug shortage isn’t new — and neither are the solutions

Be careful with at

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Mark Cuban is blaming the wrong people for high drug costs

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Male doctors called my cancer incurable. A female doctor showed it wasn't

As demand for Covid shots wanes, Moderna seeks its next success

FDA early review: GLP

focus

Patients, digital health players weigh in on FTC's data privacy plan

Hospital chaplains balance Covid safety with patients’ spiritual needs

Does Paxlovid work in people vaccinated against Covid

Profiling embryos to choose those with higher IQs is almost a reality

Nonprofit, backed by Microsoft, to certify AI tools in health care

Biogen’s boardroom scandal saddles CEO with first crisis

leisure time

focus

explore

hotspot